logo
Auto companies 'in full panic' over rare-earths bottleneck

Auto companies 'in full panic' over rare-earths bottleneck

CBC2 days ago

Social Sharing
Frank Eckard, CEO of a German magnet maker, has been fielding a flood of calls in recent weeks. Exasperated automakers and parts suppliers have been desperate to find alternative sources of magnets, which are in short supply due to Chinese export curbs.
Some told Eckard their factories could be idled by mid-July without backup magnet supplies.
"The whole car industry is in full panic," said Eckard, CEO of Magnosphere, based in Troisdorf, Germany. "They are willing to pay any price."
Car executives have once again been driven into their war rooms, concerned that China's tight export controls on rare-earth magnets — crucially needed to make cars — could cripple production.
U.S. President Donald Trump said Friday that Chinese President Xi Jinping agreed to let rare earths minerals and magnets flow to the United States. A U.S. trade team is scheduled to meet Chinese counterparts for talks in London on Monday.
The industry worries that the rare-earths situation could cascade into the third massive supply chain shock in five years. A semiconductor shortage wiped away millions of cars from automakers' production plans, from roughly 2021 to 2023. Before that, the coronavirus pandemic in 2020 shut factories for weeks.
Those crises prompted the industry to fortify supply chain strategies. Executives have prioritized backup supplies for key components and reexamined the use of just-in-time inventories, which save money but can leave them without stockpiles when a crisis unfurls.
Judging from Eckard's inbound calls, though, "nobody has learned from the past," he said.
This time, as the rare-earths bottleneck tightens, the industry has few good options, given the extent to which China dominates the market.
The fate of automakers' assembly lines has been left to a small team of Chinese bureaucrats as it reviews hundreds of applications for export permits.
Several European auto-supplier plants have already shut down, with more outages coming, said the region's auto supplier association, CLEPA.
"Sooner or later, this will confront everyone," said CLEPA secretary-general Benjamin Krieger.
Cars today use rare-earths-based motors in dozens of components — side mirrors, stereo speakers, oil pumps, windshield wipers, and sensors for fuel leakage and braking sensors.
China controls up to 70 per cent of global rare-earths mining, 85 per cent of refining capacity and about 90 per cent of rare-earth metal alloy and magnet production, consultancy AlixPartners said.
The average electric vehicle uses about 0.5 kg of rare earth elements, and a fossil-fuel car uses just half that, according to the International Energy Agency.
China has clamped down before, including in a 2010 dispute with Japan, during which it curbed rare-earths exports. Japan had to find alternative suppliers, and by 2018, China accounted for only 58 per cent of its rare earth imports.
"China has had a rare-earth card to play whenever they wanted to," said Mark Smith, CEO of mining company NioCorp, which is developing a rare-earth project in Nebraska scheduled to start production within three years.
Across the industry, automakers have been trying to wean off China for rare-earth magnets, or even develop magnets that do not need those elements. But most efforts are years away from the scale needed.
"It's really about identifying ... and finding alternative solutions" outside China, Joseph Palmieri, head of supply chain management at supplier Aptiv, said at a conference in Detroit last week.
Automakers including General Motors and BMW and major suppliers such as ZF and BorgWarner are working on motors with low-to-zero rare-earth content, but few have managed to scale production enough to cut costs.
The EU has launched initiatives including the Critical Raw Materials Act to boost European rare-earth sources. But it has not moved fast enough, said Noah Barkin, a senior advisor at Rhodium Group, a China-focused U.S. think tank.
Even players that have developed marketable products struggle to compete with Chinese producers on price. David Bender, co-head of German metal specialist Heraeus' magnet recycling business, said it is only operating at one per cent capacity and will have to close next year if sales do not increase.
Minneapolis-based Niron has developed rare-earth free magnets and has raised more than US $250 million from investors including GM, Stellantis and auto supplier Magna.
"We've seen a step change in interest from investors and customers" since China's export controls took effect, CEO Jonathan Rowntree said. It is planning a US $1 billion plant scheduled to start production in 2029.
England-based Warwick Acoustics has developed rare-earth-free speakers expected to appear in a luxury car later this year. CEO Mike Grant said the company has been in talks with another dozen automakers, although the speakers are not expected to be available in mainstream models for about five years.
As auto companies scout longer-term solutions, they are left scrambling to avert imminent factory shutdowns. Automakers must figure out which of their suppliers — and smaller ones a few links up the supply chain — need export permits. Mercedes-Benz, for example, is talking to suppliers about building rare-earth stockpiles.
Analysts said the constraints could force automakers to make cars without certain parts and park them until they become available, as GM and others did during the semiconductor crisis.
Automakers' reliance on China does not end with rare earth elements. A 2024 European Commission report said China controls more than 50 per cent of global supply of 19 key raw materials, including manganese, graphite and aluminum.
Andy Leyland, co-founder of supply chain specialist SC Insights, said any of those elements could be used as leverage by China. "This just is a warning shot," he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI Tool 'KIBIT': A Game Changer in New Drug Development
AI Tool 'KIBIT': A Game Changer in New Drug Development

Japan Forward

timean hour ago

  • Japan Forward

AI Tool 'KIBIT': A Game Changer in New Drug Development

このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む

Canada, China, Mexico, Japan and EU urge Trump not to impose new airplane tariffs
Canada, China, Mexico, Japan and EU urge Trump not to impose new airplane tariffs

Globe and Mail

time2 hours ago

  • Globe and Mail

Canada, China, Mexico, Japan and EU urge Trump not to impose new airplane tariffs

Five nations and the European Union, as well as airlines and aerospace firms worldwide, urged the Trump administration not to impose new national security tariffs on imported commercial planes and parts, documents released on Tuesday showed. Airlines and planemakers have been lobbying President Donald Trump to restore the tariff-free regime under the 1979 Civil Aircraft Agreement that has yielded an annual trade surplus of US$75 billion for the U.S. industry. The documents made public by the U.S. Commerce Department bared concerns over the fallout of possible new tariffs expressed by companies as well as nations such as Canada, China, Japan, Mexico and Switzerland, besides the European Union. 'As reliable trading partners, the European Union and United States should strengthen their trade regarding aircraft and aircraft parts, rather than hinder it by imposing trade restrictions,' the EU wrote. It would consider its options 'to ensure a level playing field,' it added. Trump has already imposed tariffs of 10 per cent on nearly all airplane and parts imports. 'No country or region should attempt to support the development of its domestic aircraft manufacturing industry by suppressing foreign competitors,' the Chinese government wrote. Separately, U.S. planemaker Boeing cited a recent trade deal unveiled in May with Britain that ensures tariff-free treatment for airplanes and parts. Opinion: Carney was right to not retaliate against Trump's latest tariffs 'The United States should ensure duty-free treatment for commercial aircraft and their parts in any negotiated trade agreement, similar to its efforts with the United Kingdom,' Boeing told the Commerce Department in a filing. Mexico said in 2024 it exported US$1.45 billion in aircraft parts, just a tenth of the total, to the United States. The EU said it took U.S. exports of aircraft worth roughly US$12 billion, while exporting about $8 billion of aircraft to the U.S. In early May, the Commerce Department launched a 'Section 232' national security investigation into imports of commercial aircraft, jet engines and parts that could form the basis for even higher tariffs on such imports. Last week, Delta Air Lines and major trade groups warned of tariffs' impact on ticket prices, aviation safety and supply chains. 'Current U.S. tariffs on aviation are putting domestic production of commercial aircraft at risk,' Airbus Americas CEO Robin Hayes said in a filing. 'It is not realistic or sensible today to create a 100 per cent domestic supply chain in any country.' Boeing said it had been increasing U.S. content in its airplanes over the last decade and its newest airplanes, the 737 MAX 10 and 777X, would have 'more than 88 per cent domestically-sourced content.' The United Auto Workers union, which represents 10,000 aerospace workers, said it supports tariffs and domestic production quotas, adding that U.S. aerospace employment has fallen to 510,000 in 2024 from 850,000 in 1990. 'To safeguard the entire aerospace supply chain across the commercial and defense sectors, comprehensive tariffs and production quotas on several products are needed,' it said. JetBlue Airways opposed new tariffs, however, saying, 'Trade policy should reinforce, not destabilize, the proven systems that keep our aircraft flying safely and affordably.'

Asia shares climb after China and the US say they have a framework for seeking a trade deal
Asia shares climb after China and the US say they have a framework for seeking a trade deal

Winnipeg Free Press

time3 hours ago

  • Winnipeg Free Press

Asia shares climb after China and the US say they have a framework for seeking a trade deal

TOKYO (AP) — Asian shares mostly rose Wednesday after China and the U.S. said they had reached agreement on a framework for following up on the trade truce reached last month in Geneva. Japan's benchmark Nikkei 225 surged 0.5% in morning trading to 38,385.37. Data from the Bank of Japan data showed wholesale inflation slowed in May, meaning there might be less pressure for the central bank to raise interest rates in its next policy board meeting. Hong Kong's Hang Seng gained 0.8% to 24,364.77, while the Shanghai Composite rose 0.5% to 3,402.72. Australia's S&P/ASX 200 edged up 0.3% to 8,612.40. South Korea's Kospi added 0.6% to 2,889.88. Tuesday on Wall Street, the S&P 500 rose 0.5% to 6,038.81 as the trade talks between the world's two largest economies carried into a second day. The Dow Jones Industrial Average added 0.2% to 42,866.87, and the Nasdaq composite gained 0.6% to 19,714.99. Stocks have roared higher since dropping roughly 20% below their record two months ago, when President Donald Trump shocked financial markets with his announcement of tariffs that were so stiff that they raised worries about a possible recession. Much of the rally has been due to hopes that Trump would lower his tariffs after reaching trade deals with countries around the world, and the S&P 500 is back within 1.7% of its record set in February. Analysts said that after two days of discussion in London, the late-night agreement reached appeared to be a consensus on what was already agreed upon before. 'So what did 48 hours of talks actually produce? Apparently, a reaffirmation to eventually do what they had already said they would do. If markets were expecting substance, they got process instead,' said Stephen Innes, managing partner at SPI Asset Management. U.S. Secretary of Commerce Howard Lutnick said Tuesday evening in London that talks with China were going 'really, really well.' Both the United States and China have put many of their tariffs announced against each other on pause as talks continue. Even though many tariffs are on hold for the moment, uncertainty over what is to come is still affecting companies and their ability to make profits. Designer Brands, the company behind the DSW shoe store chain, became the latest U.S. company to yank its financial forecasts for 2025 because of 'uncertainty stemming primarily from global trade policies.' The company, which also owns the Keds, Jessica Simpson and other shoe brands, reported a larger loss for the start of the year than analysts were expecting, and its revenue also fell short of forecasts. CEO Doug Howe pointed to 'persistent instability and pressure on consumer discretionary' spending, and the company's stock tumbled 18.2%. The uncertainty is moving in both directions, to be sure. A survey released Tuesday of optimism among small U.S. businesses improved a bit in May. 'While the economy will continue to stumble along until the major sources of uncertainty are resolved, owners reported more positive expectations on business conditions and sales growth,' according to Bill Dunkelberg, chief economist at the National Federation of Independent Business. Tesla helped to make up for such losses by rising 5.7%. The electric vehicle company has been recovering since tumbling last week as Elon Musk's relationship with Trump imploded. That raised fear about possible retaliation by the U.S. government against Tesla. Shares that trade in the United States of chipmaking giant Taiwan Semiconductor Manufacturing Co. rose 2.6% after the company known as TSMC said its revenue in May jumped nearly 40% from the year earlier. Monday Mornings The latest local business news and a lookahead to the coming week. In other dealings early Wednesday, the yield on the 10-year Treasury eased to 4.48% from 4.47% late Tuesday. Benchmark U.S. crude oil slipped 12 cents to $64.86 a barrel. Brent crude, the international standard, fell 15 cents to $66.72 a barrel. The U.S. dollar rose to 144.94 Japanese yen from 144.84 yen. The euro cost $1.1414, down from $1.1425. ___ AP Business Writer Stan Choe contributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store